Literature DB >> 11689489

Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients.

K Sathasivam1, B Woodman, A Mahal, F Bertaux, E E Wanker, D T Shima, G P Bates.   

Abstract

Huntington's disease (HD) is a progressive neurological disorder caused by a CAG/polyglutamine repeat expansion. We have previously generated the R6/2 mouse model that expresses exon 1 of the human HD gene containing CAG repeats in excess of 150. These mice develop a progressive neurological phenotype with a rapid onset and progression. We show here that it is impossible to establish fibroblast lines from these mice at 12 weeks of age, whilst this can be achieved without difficulty at 6 and 9 weeks. Cultures derived from mice at 12 weeks contained a high frequency of dysmorphic cells, including cells with an aberrant nuclear morphology and a high frequency of micronuclei and large vacuoles. All of these features were also present in a line derived from a juvenile HD patient. Fibroblast lines derived from R6/2 mice and from HD patients were found to have a high frequency of multiple centrosomes which could account for all of the observed phenotypes including a reduced mitotic index, high frequency of aneuploidy and persistence of the midbody. We were unable to detect large insoluble polyglutamine aggregates in either the mouse or human lines. We have identified a novel progressive HD pathology that occurs in cells of non-central nervous system origin. An investigation of the pathological consequences of the HD mutation in these cells will provide insight into cellular basis of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689489     DOI: 10.1093/hmg/10.21.2425

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  42 in total

Review 1.  Functions and dysfunctions of the mammalian centrosome in health, disorders, disease, and aging.

Authors:  Heide Schatten; Qing-Yuan Sun
Journal:  Histochem Cell Biol       Date:  2018-07-30       Impact factor: 4.304

2.  A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.

Authors:  Xiaoqian Zhang; Donna L Smith; Anatoli B Meriin; Sabine Engemann; Deborah E Russel; Margo Roark; Shetia L Washington; Michele M Maxwell; J Lawrence Marsh; Leslie Michels Thompson; Erich E Wanker; Anne B Young; David E Housman; Gillian P Bates; Michael Y Sherman; Aleksey G Kazantsev
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-10       Impact factor: 11.205

3.  Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells.

Authors:  Francisco J Diaz-Corrales; Masato Asanuma; Ikuko Miyazaki; Ko Miyoshi; Nobutaka Hattori; Norio Ogawa
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

4.  Serine 421 regulates mutant huntingtin toxicity and clearance in mice.

Authors:  Ian H Kratter; Hengameh Zahed; Alice Lau; Andrey S Tsvetkov; Aaron C Daub; Kurt F Weiberth; Xiaofeng Gu; Frédéric Saudou; Sandrine Humbert; X William Yang; Alex Osmand; Joan S Steffan; Eliezer Masliah; Steven Finkbeiner
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

5.  Allele-specific silencing of mutant Huntington's disease gene.

Authors:  Yu Zhang; Joshua Engelman; Robert M Friedlander
Journal:  J Neurochem       Date:  2009-01       Impact factor: 5.372

6.  CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse.

Authors:  I Dragatsis; D Goldowitz; N Del Mar; Y P Deng; C A Meade; Li Liu; Z Sun; P Dietrich; J Yue; A Reiner
Journal:  Neurobiol Dis       Date:  2008-11-06       Impact factor: 5.996

7.  Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Hilary Moffitt; Graham D McPhail; Ben Woodman; Carl Hobbs; Gillian P Bates
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

8.  Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease.

Authors:  Kirupa Sathasivam; Amin Lane; Justin Legleiter; Alice Warley; Ben Woodman; Steve Finkbeiner; Paolo Paganetti; Paul J Muchowski; Stuart Wilson; Gillian P Bates
Journal:  Hum Mol Genet       Date:  2010-01-01       Impact factor: 6.150

9.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.

Authors:  Emma Hockly; Victoria M Richon; Benjamin Woodman; Donna L Smith; Xianbo Zhou; Eddie Rosa; Kirupa Sathasivam; Shabnam Ghazi-Noori; Amarbirpal Mahal; Philip A S Lowden; Joan S Steffan; J Lawrence Marsh; Leslie M Thompson; Cathryn M Lewis; Paul A Marks; Gillian P Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

10.  Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Christian Landles; Andreas Weiss; Sophie Franklin; David Howland; Gill Bates
Journal:  PLoS Curr       Date:  2012-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.